The development of novel molecularly targeted cancer therapeutics remains slow and
expensive with many late-stage failures. There is an urgent need to accelerate this process …

Abstract The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC)
charged the Biomarker Task Force to develop recommendations to improve the decisions …

The idea for this book came from the time the authors spent at the Statistics and Applied
Mathematical Sciences Institute (SAMSI) in Research Triangle Park in North Carolina …

Geographic atrophy is an advanced form of age-related macular degeneration (AMD) and a
leading cause of vision loss for which there are no approved treatments. Genetic studies in …

Rituximab plus intravenous bolus chemotherapy is a standard treatment for
immunocompetent patients with B-cell non-Hodgkin lymphoma (NHL). Some studies have …

Background Combining targeted treatments for renal cell carcinoma has been suggested as
a possible method to improve treatment efficacy. We aimed to assess the potential …

Background Population pharmacokinetic data suggest axitinib plasma exposure correlates
with efficacy in metastatic renal-cell carcinoma. Axitinib dose titration might optimise …

Studies that are unimpeachably thorough, non-political, unbiased, and properly designed
These are the standards to which everyone in clinical research aspires. Yet, the difficulties in …

Attrition is a major issue in anticancer drug development with up to 95% of drugs tested in
Phase I trials not reaching a marketing authorisation making the drug development process …

Background: Bryostatin-activated PKC epsilon pre-clinically induces synaptogenesis, anti-
apoptosis, anti-amyloid-β oligomers, and anti-hyperphosphorylated tau. Objectives: To …